Lupin Launches Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in the United States

Global pharma major Lupin Limited (Lupin) today announced the launch of Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets, 5 mg/500 mg, 5 mg/1,000 mg, 10 mg/500 mg, 10 mg/1,000 mg in the United States following the approval for its Abbreviated New Drug Application from the U.S. FDA as bioequivalent to Xigduo® XR for the indications in the approved labeling.

Shares of Lupin Limited was last trading in BSE at Rs. 2307.55 as compared to the previous close of Rs. 2311.75. The total number of shares traded during the day was 28578 in over 3637 trades.

The stock hit an intraday high of Rs. 2317.00 and intraday low of 2286.20. The net turnover during the day was Rs. 65856543.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 Pharmaceuticals Dapagliflozin MetforminHydrochloride ExtendedReleaseTablets